Cardiovascular Drugs Practice Questions

Q: In which of the following conditions is digoxin most likely to accumulate to toxic levels?

Renal insufficiency. ***Renal insufficiency*** - **Digoxin** is primarily excreted unchanged by the **kidneys**, so impaired renal function significantly prolongs its half-life and leads to drug accumulation. - Patients with kidney failure require **dose adjustments** or closer monitoring of **digoxin levels** to prevent toxicity. *Chronic hepatitis* - **Chronic hepatitis** primarily affects the **liver's metabolic capacity**, which is not the primary route of **digoxin elimination**. - While severe hepatic dysfunction can subtly impact drug disposition, it's not the main reason for **digoxin accumulation** like **renal insufficiency**. *Advanced cirrhosis* - **Advanced cirrhosis** involves severe liver dysfunction, which can alter drug metabolism and protein binding. - However, **digoxin's elimination** is mainly renal, so liver disease alone does not typically lead to significant accumulation unless accompanied by **renal impairment**. *Chronic pancreatitis* - **Chronic pancreatitis** is a disorder of the pancreas and does not directly impact the **excretion or metabolism** of **digoxin**. - It would not be expected to cause **digoxin accumulation** to toxic levels.

Q: Which of the following antiarrhythmic drugs is contraindicated in a patient with interstitial lung disease?

Amiodarone. ***Amiodarone*** - **Amiodarone** is contraindicated in patients with interstitial lung disease due to its well-known and potentially severe pulmonary toxicity, which can exacerbate or induce **pulmonary fibrosis**. - Its long half-life means that drug accumulation and persistent adverse effects, including **ILD exacerbation**, are significant concerns. *Sotalol* - **Sotalol** primarily carries risks of **prolonged QT interval** and **torsades de pointes** because it has both beta-blocking and Class III antiarrhythmic properties. - While it has cardiac and minor non-cardiac side effects, it is not specifically known to cause or worsen **interstitial lung disease**. *Lignocaine* - **Lignocaine** (lidocaine) is a Class Ib antiarrhythmic primarily used for **ventricular arrhythmias**, especially in acute settings. - Its adverse effects are mainly **neurological** (e.g., dizziness, seizures at high doses) and **cardiovascular** (e.g., hypotension, bradycardia), with no significant association with lung disease. *Quinidine* - **Quinidine** is a Class Ia antiarrhythmic that can cause a variety of side effects, including **gastrointestinal upset**, **cinchonism** (tinnitus, blurred vision), and **cardiac rhythm disturbances**. - While it can rarely cause a hypersensitivity pneumonitis, it is not a primary concern or contraindication in existing **interstitial lung disease** compared to amiodarone.

Q: Clonidine is used as an antihypertensive agent, but if used as a fast intravenous injection, it can increase blood pressure due to:

Agonistic action on vascular Alpha 2 adrenergic receptors. ***Agonistic action on vascular Alpha 2 adrenergic receptors*** - When administered rapidly intravenously, clonidine initially acts as an agonist on **postsynaptic α2-adrenergic receptors** in the vascular smooth muscle. - This direct peripheral vasoconstrictive effect occurs before central effects dominate, leading to a transient increase in blood pressure. *Stimulation of the vasomotor center leading to increased sympathetic output* - Clonidine's primary antihypertensive effect is through **central α2-receptor agonism**, which *decreases* sympathetic outflow from the vasomotor center. - It would not stimulate the vasomotor center to *increase* sympathetic output, as this contradicts its fundamental mechanism of action. *Cardiac stimulation* - Clonidine is known for its **cardiac depressant effects** due to reduced sympathetic outflow, leading to decreased heart rate and contractility. - It does not directly stimulate the heart, and any initial blood pressure rise is due to vascular effects, not increased cardiac output. *Release of noradrenaline from adrenergic nerve endings* - Clonidine is an **α2-adrenergic agonist**, and activation of presynaptic α2-receptors typically *inhibits* the release of noradrenaline. - It does not cause a direct release of noradrenaline but rather modulates its release in the opposite direction.

Q: Which of the following vitamins can be used in high doses to treat hypercholesterolemia?

Niacin. ***Niacin*** - **Niacin** (Vitamin B3) in pharmacological doses effectively lowers **LDL cholesterol** and triglycerides while raising **HDL cholesterol**. - Its mechanism involves inhibiting **hepatic VLDL secretion** and decreasing the catabolism of **HDL**. *Vitamin B2* - **Vitamin B2** (riboflavin) is crucial for **cellular energy production** and acts as a cofactor in various enzyme reactions. - It does not have a significant role in **lipid metabolism** or in treating **hypercholesterolemia** at high doses. *Vitamin B5* - **Vitamin B5** (pantothenic acid) is a component of **coenzyme A**, essential for **fatty acid synthesis** and breakdown. - While involved in metabolism, it is not used therapeutically to manage **hypercholesterolemia**. *Vitamin B1* - **Vitamin B1** (thiamine) is vital for **carbohydrate metabolism** and **nerve function**. - There is no evidence supporting its use in treating **hypercholesterolemia**.

Q: Statins act on:

HMG CoA reductase. ***HMG CoA reductase*** - **HMG-CoA reductase inhibitors** (statins) are the most effective and widely used class of hypolipidemic agents [1, 2, 3]. - This enzyme is the **rate-limiting step** in cholesterol biosynthesis in the liver [1, 2, 3]. *HMG CoA synthetase* - HMG-CoA synthetase is involved in the synthesis of **HMG-CoA** from acetyl-CoA and acetoacetyl-CoA. - This enzyme precedes the HMG-CoA reductase step and is **not the primary target** for cholesterol-lowering drugs. *Squalene epoxidase* - Squalene epoxidase is an enzyme involved in the later stages of the **cholesterol synthesis pathway**, specifically in converting squalene to squalene epoxide. - While inhibition of this enzyme would reduce cholesterol synthesis, it is **not the main target** of current widely used hypolipidemic agents. *HMG CoA hydratase* - HMG-CoA hydratase (also known as HMG-CoA lyase) is involved in the breakdown of HMG-CoA into **acetyl-CoA and acetoacetate** in ketogenesis. - It is **not directly involved** in the main pathway of cholesterol synthesis that is targeted by current hypolipidemic drugs.

Q: Dobutamine mainly acts on which receptor:

Beta 1. ***Beta 1*** - **Dobutamine** is a direct-acting **beta-1 adrenergic agonist**, which means it primarily stimulates beta-1 receptors. - Stimulation of **beta-1 receptors** in the heart leads to increased **cardiac contractility** (positive inotropy) and heart rate (positive chronotropy), making it useful in conditions like **heart failure**. *Beta 2* - **Beta-2 receptors** are primarily found in the lungs and **vascular smooth muscle**. - Stimulation of **beta-2 receptors** causes **bronchodilation** and **vasodilation**, effects that are not the primary therapeutic goal of dobutamine. *Alpha 1* - **Alpha-1 receptors** are mainly located in **vascular smooth muscle** and cause **vasoconstriction** when stimulated. - While dobutamine may have some weak effects on alpha-1 receptors at higher doses, its dominant action is on beta-1 receptors, and significant vasoconstriction is not its primary clinical effect. *Alpha 2* - **Alpha-2 receptors** are largely presynaptic and act to inhibit the release of **norepinephrine**. - **Dobutamine** has minimal to no significant activity at **alpha-2 receptors**.

Q: All of the following are centrally acting antihypertensive drugs except:

Trimethoprim. ***Trimethoprim*** - **Trimethoprim** is an **antibiotic** and is not used as an antihypertensive drug. - It works by inhibiting **dihydrofolate reductase**, an enzyme involved in bacterial folate synthesis. *Methyldopa* - **Methyldopa** is a **centrally acting alpha-2 adrenergic agonist** that reduces sympathetic outflow from the central nervous system. - It decreases peripheral vascular resistance and heart rate, leading to a reduction in blood pressure. *Clonidine* - **Clonidine** is a **centrally acting alpha-2 adrenergic agonist** that stimulates alpha-2 receptors in the brainstem. - This stimulation reduces sympathetic outflow, leading to vasodilation and decreased heart rate. *Guanabenz* - **Guanabenz** is also a **centrally acting alpha-2 adrenergic agonist**. - It acts similarly to clonidine by stimulating central alpha-2 receptors to decrease sympathetic tone and lower blood pressure.

Q: Most common digoxin-induced arrhythmia is

Ventricular Premature Beats. ***Ventricular Premature Beats (VPBs)*** - **Most common** digoxin-induced arrhythmia overall, occurring in up to 50-90% of digoxin toxicity cases. - Digoxin increases intracellular calcium through Na+/K+-ATPase inhibition, leading to **increased automaticity** and **delayed afterdepolarizations** that trigger ventricular ectopy. - **Hypokalemia** (common with concurrent diuretic use) significantly increases the risk by enhancing digoxin binding to Na+/K+-ATPase and further elevating intracellular calcium. - VPBs can manifest in various patterns including isolated beats, couplets, or organized patterns like ventricular bigeminy. *Ventricular bigeminy* - While ventricular bigeminy (every other beat is a VPB) is highly **characteristic** and specific for digoxin toxicity, it is a specific *pattern* of VPBs rather than the most common arrhythmia overall. - Represents severe ventricular irritability and indicates significant digoxin effect, but occurs less frequently than isolated VPBs. - When present, it strongly suggests digoxin toxicity and warrants immediate attention. *Ventricular Fibrillation* - A rare but **life-threatening** complication of severe digoxin toxicity. - Usually preceded by other ventricular arrhythmias (VPBs, ventricular tachycardia) and represents advanced toxicity. - Not common enough to be considered the "most common" digoxin-induced arrhythmia. *Atrial Flutter* - Digoxin can cause various atrial arrhythmias, but atrial flutter is relatively uncommon. - The most characteristic **atrial** arrhythmia in digoxin toxicity is **paroxysmal atrial tachycardia (PAT) with AV block**, not atrial flutter. - Digoxin's primary atrial effect is to slow AV nodal conduction, which may actually help control atrial flutter rather than cause it.

Q: Effects of beta blockers on the heart are all of the following except:

Decreases duration of systole. ***Decreases duration of systole*** - Beta-blockers primarily prolong the **duration of systole** by extending the **ejection time** and slowing ventricular relaxation. - They also increase the **diastolic filling time** by reducing heart rate, impacting overall cardiac cycle duration. *Decrease in heart rate* - Beta-blockers block **beta-1 adrenergic receptors** in the heart, leading to a decrease in **sympathetic stimulation** and thus a reduced heart rate. - This effect is beneficial in conditions like **tachycardia** and **angina**, as it reduces myocardial oxygen demand. *May decrease cardiac output initially.* - By reducing heart rate and contractility, beta-blockers can initially decrease **cardiac output**, especially in patients with pre-existing **ventricular dysfunction**. - This effect is often transient, as chronic use can lead to beneficial remodeling and improved efficiency in some conditions. *May precipitate heart failure in acute settings.* - In patients with acutely decompensated heart failure or severe left ventricular dysfunction, beta-blockers can acutely worsen cardiac function due to their **negative inotropic effects**. - Therefore, beta-blockers are typically initiated cautiously at low doses in stable heart failure patients and are contraindicated in acute decompensation.

Q: HMG-CoA reductase is inhibited by:

Lovastatin. ***Lovastatin*** - **Lovastatin** is part of the statin class of drugs, which are potent competitive inhibitors of **HMG-CoA reductase**. - By inhibiting this enzyme, statins reduce the synthesis of **mevalonate**, a precursor to **cholesterol**, thereby lowering LDL-cholesterol levels. *Gemfibrozil* - **Gemfibrozil** is a **fibrate**, a class of drugs that primarily act by activating **peroxisome proliferator-activated receptor alpha (PPAR-α)**. - Its main effect is to decrease **triglyceride** levels and increase **HDL cholesterol**, not directly inhibit HMG-CoA reductase. *Clofibrate* - **Clofibrate** is also a **fibrate** and operates similarly to gemfibrozil by activating **PPAR-α**. - It primarily reduces **triglycerides** and has a modest effect on increasing HDL, but does not inhibit HMG-CoA reductase. *Nicotinic acid* - **Nicotinic acid** (niacin or vitamin B3) reduces hepatic synthesis of **VLDL** and inhibits the release of **fatty acids** from adipose tissue. - This leads to a decrease in **LDL cholesterol** and triglycerides, and an increase in **HDL cholesterol**, but it does not directly inhibit HMG-CoA reductase.

Question 1

In which of the following conditions is digoxin most likely to accumulate to toxic levels?

Accepted Answer

Renal insufficiency

Answer

Chronic hepatitis

Answer

Advanced cirrhosis

Answer

Chronic pancreatitis

Question 2

Which of the following antiarrhythmic drugs is contraindicated in a patient with interstitial lung disease?

Accepted Answer

Amiodarone

Answer

Lignocaine

Answer

Sotalol

Answer

Quinidine

Question 3

Clonidine is used as an antihypertensive agent, but if used as a fast intravenous injection, it can increase blood pressure due to:

Accepted Answer

Agonistic action on vascular Alpha 2 adrenergic receptors

Answer

Cardiac stimulation

Answer

Stimulation of the vasomotor center leading to increased sympathetic output

Answer

Release of noradrenaline from adrenergic nerve endings

Question 4

Which of the following vitamins can be used in high doses to treat hypercholesterolemia?

Accepted Answer

Niacin

Answer

Vitamin B2

Answer

Vitamin B5

Answer

Vitamin B1

Question 5

Statins act on:

Accepted Answer

HMG CoA reductase

Answer

HMG CoA synthetase

Answer

HMG CoA hydratase

Answer

Squalene epoxidase

Question 6

Dobutamine mainly acts on which receptor:

Accepted Answer

Beta 1

Answer

Beta 2

Answer

Alpha 1

Answer

Alpha 2

Question 7

All of the following are centrally acting antihypertensive drugs except:

Accepted Answer

Trimethoprim

Answer

Methyldopa

Answer

Clonidine

Answer

Guanabenz

Question 8

Most common digoxin-induced arrhythmia is

Accepted Answer

Ventricular Premature Beats

Answer

Ventricular bigeminy

Answer

Atrial Flutter

Answer

Ventricular Fibrillation

Question 9

Effects of beta blockers on the heart are all of the following except:

Accepted Answer

Decreases duration of systole

Answer

Decrease in heart rate

Answer

May decrease cardiac output initially.

Answer

May precipitate heart failure in acute settings.

Question 10

HMG-CoA reductase is inhibited by:

Accepted Answer

Lovastatin

Answer

Gemfibrozil

Answer

Nicotinic acid

Answer

Clofibrate

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?